ArticleInvestigational new drugs2016

A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.

Karen W L Yee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.